The PERMIT1 Study was a prospective, open-label, nonrandomized clinical study. Twenty consecutive patients with scar VT underwent © 2012 American Heart Association, Inc. Background-Percutaneous left ventricular assist devices (pLVADs) are increasingly being used to facilitate ablation of unstable ventricular tachycardia (VT), but the safety profile and hemodynamic benefits of these devices have not been described in a systematic, prospective manner. Methods and Results-Twenty patients with scar VT underwent ablation with a pLVAD. Neuromonitoring using cerebral oximetry was performed to evaluate a cerebral desaturation threshold to guide the duration of activation/entrainment mapping. The efficacy of pLVAD support was tested in a controlled manner with simulated VT. Complete procedural success was achieved in 50% (n=8) of patients, who were initially inducible for sustained VT, and partial procedural success in 37% (n=6). Using a cerebral desaturation level of 55% as a lower safety limit to guide the duration of sustained VT, 3 patients (15%) developed mild acute kidney injury (all resolved), and 1 (5%) patient developed mild cognitive dysfunction. During fast simulated VT (300 ms), cerebral desaturation to ≤55% occurred in more than half (53%) of patients tested without pLVAD support, compared with only 5% with full pLVAD support (P=0.003). ablation between September 2010 and July 2011. The inclusion criteria were men or women aged 18 to 90 years with monomorphic VT and recurrent appropriate implantable cardioverter defibrillator therapies and a left ventricular ejection fraction ≤40%. Patients were excluded if any of the following was present: (1) a reversible cause of VT or evidence of ongoing ischemia causing VT, (2) a cerebral ischemic event within the preceding month, (3) mural thrombus in the left ventricle, (4) a mechanical aortic valve or severe aortic stenosis (aortic valve area < 1.0 cm 2 ), (5) any condition resulting in an absolute contraindication to anticoagulation, (6) life expectancy of <1 year, or (7) pregnancy. The institutional review board approved the study. Patients were enrolled after obtaining written informed consent for participation in the study and the catheter ablation procedure. The trial was registered at http://www.clinicaltrials.gov (No. NCT01294267; Mount Sinai Medical Center, New York, NY).
H emodynamic instability precludes mapping during ventricular tachycardia (VT) in a majority of patients with structural heart disease. 1, 2 Although repetitive inductions and terminations can facilitate brief episodes of entrainment and activation mapping, such a strategy can have a negative cumulative effect and expose patients to end-organ hypoperfusion, progressive hemodynamic collapse, and acute decompensated heart failure, without necessarily improving the ability to identify the critical VT isthmus. As such, there has been increased interest and use of percutaneous cardiac assist devices during mapping and ablation of scar-related VT. 3, 4 We recently demonstrated that patients undergoing percutaneous left ventricular assist devices (pLVAD)-supported scar VT ablation could be maintained in VT significantly longer than patients without pLVAD support and do so without compromising end-organ tissue perfusion. 5 However, this was a retrospective analysis, and the precise ability of pLVADs to facilitate mapping during unstable VT (uVT) remains unknown. Furthermore, commonly used techniques to monitor adequate perfusion, such as arterial lactate levels, pulse oximetry, or mean arterial pressure (MAP), are either not dynamic enough or lack optimal safe threshold values to guide mapping and ablation of uVT, particularly in the setting of pLVAD hemodynamic support. Therefore, the Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation (PERMIT1) Study was designed to (1) assess the safety and short-term efficacy of pLVAD support during mapping and ablation of uVT in patients with significant left ventricular dysfunction, and (2) establish a safe threshold for the maintenance of uVT, by using the brain as an index organ and a marker of global tissue perfusion.
Procedural Characteristics
All procedures were performed under general anesthesia with endotracheal intubation. A radial artery catheter was used for continuous blood pressure monitoring. Vasoactive drugs, most commonly phenylephrine and norepinephrine, were administered at the discretion of the anesthesiologist to target a MAP of at least 50 to 60 mm Hg during episodes of VT. Arterial lactate levels were drawn at the start of the case and then immediately at the end of the procedure. Bilateral cerebral tissue oxygen saturation (SctO2) was noninvasively measured and recorded throughout the entire case (FORE-SIGHT, CASMED, Branford, MT). Preinduction baseline SctO2 values were recorded while breathing room air (SctO2 ra ) and then again following intubation at a 100% fraction of inspired oxygen (FiO 2 ) (SctO2 100 ). An FiO 2 of 100% was maintained throughout the entire case.
Mapping and ablation were performed with a magnetic-based electroanatomic system (Carto3, Biosense Webster, Diamond Bar, CA) and a 3.5-mm externally irrigated ablation catheter (Navistar Thermocool, Biosense Webster). Epicardial access and mapping (n=10/20) were performed before the transseptal puncture or insertion of the pLVAD. Left ventricular endocardial mapping was performed with a transseptal approach using an 8.5-Fr steerable sheath (Agilis, large curve, St. Jude Medical, St. Paul, MN). After transseptal access, heparin was administered to maintain an ACT of 250 to 300 seconds, and the pLVAD (Impella 2.5, Abiomed Inc, Danvers, MA) was inserted percutaneously through a 13-Fr sheath. The Preclose technique for arteriotomy site closure was used after left iliofemoral angiography at the start of the case. Device positioning in the left ventricle was confirmed with fluoroscopy and intracardiac echocardiography (Acunav, Biosense Webster, Diamond Bar, CA). The anticoagulation protocol for patients undergoing epicardial and endocardial mapping has been described previously. 8 Direct left atrial pressures were measured before insertion of the pLVAD and at the end of the procedure at full-support (P8) for 15 to 20 minutes (following the most recent episode of VT).
Simulated VT (siVT), Pacing Protocol
To assess the efficacy of pLVAD support on cerebral perfusion during tachycardia in a controlled manner, cerebral oxygenation was measured in all patients during siVT at 3 cycle lengths (500, 400, and 300 ms), comparing the SctO2 with the pLVAD at full-support (P8, 1.9-2.5 L/min) and with the pLVAD providing no-support (P0, 0.0 L/ min) for 1 minute. If there was a drop in cerebral oxygen saturation to ≤55% (lower safety limit) during siVT, the pacing event was terminated prematurely (ie, before completion of 1 minute) as dictated in the predefined protocol. In between siVTs, the SctO2 was permitted to return to its baseline (prepacing) value. When siVTs were performed with no-support, the pLVAD was temporarily turned back on (typically 2-3 minutes) to assist the SctO2 values to return to baseline levels. Immediately before, and often during, the siVT episodes (especially at higher rates), the treating anesthesiologist administered phenylephrine boluses to target a mean blood pressure of at least 50 to 60 mm Hg.
Mapping and Ablation
Programmed stimulation included up to 3 extrastimuli and rapid pacing from either the right ventricle or the left ventricle. Although all inducible patients underwent a combined strategy of entrainment mapping/ablation and substrate modification, the former was the first-line approach used in this study. Specifically, the protocol dictated that patients could be mapped in VT as long as the SctO2 value remained ≥55%, irrespective of the arterial blood pressure. Once the SctO2 value trended below the threshold value of <55%, the VT had to be prematurely terminated with either pacing maneuvers or direct current cardioversion. The hemodynamics and cerebral perfusion characteristics of all VT episodes ≥3 minutes in duration were analyzed. uVT was defined as a MAP<50 mm Hg, which is generally accepted as the lower limit of normal cerebral autoregulation.
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Results of VT Ablation
Acute ablation outcomes were defined as (1) complete success: termination of the clinical (or assumed clinical) VT during ablation and noninducibility of any form of sustained VT after ablation, (2) partial success: termination of the clinical VT but persistent inducibility of other sustained VT or no termination of the clinical VT but no longer inducible for VT after ablation, (3) failure: failure at terminating the clinical VT and remained inducible for any sustained monomorphic VT after ablation. 10, 11 As previously described, a major complication was defined as an adverse event related to the procedure requiring intervention for treatment, causing long-term disability, or resulting in prolonged hospitalization within the first 30 days. 12 Specifically, this definition included pericardial effusion/tamponade, thromboembolism (cerebrovascular accident/transient ischemic attack), vascular injury (deep venous thrombosis, and femoral hematoma, fistula, or pseudoaneurysm). Postoperative cognitive dysfunction was defined as a decrease in MMSE score ≥2 points from baseline. Acute kidney injury was defined by the Acute Kidney Injury Network classification system. 13 
Statistical Analysis
Categorical variables are expressed as n (%), and comparisons assessing number of patients who reached the threshold SctO2 value ≤55% during pacing (siVT) between groups with or without pLVAD support were made using the exact version of McNemar test, to account for evaluation of paired data. Continuous variables are expressed as mean value±SD and were compared using the paired sample t test. Reductions in SctO2 from baseline during pacing (siVT) were calculated as SctO2 just before pacing-lowest SctO2 during pacing. Laboratory values are expressed as mean value at baseline (preprocedure) and mean value postprocedure, with the mean difference between groups expressed in parentheses; probability values reflect differences in mean values before versus after the procedure (paired t test). Two-sided P<0.05 was considered indicative of statistical significance. Statistical calculations were performed using SPSS 12.0 (SPSS Inc, Chicago, IL).
Results
Baseline Demographics
The baseline characteristics of the study population are shown in Table 1 . Patients were mostly men (85%; n=17) with a mean age of 58.5±11.6 years. Nearly two-thirds of patients had nonischemic cardiomyopathy (65%; n=13), and the mean left ventricular ejection fraction was 28.9±6.5%. The preprocedural functional class was evenly distributed between New York Heart Association Class III-IV (50; n=10) and Class I-II (50%; n=10) heart failure. Diabetes mellitus was present in 30% (n=6), hypertension in 70% (n= 14), chronic kidney disease in 30% (n=6), and prior CVA in 20% (n=4). At presentation, a majority of patients were taking β-blockers (80%; n=16) and Class III antiarrhythmic medications (75%; n=15), most commonly amiodarone. Nearly half of the patients (45%; n=9) underwent the procedure for VT storm, and 55% (n=11) had undergone at least one prior scar VT ablation procedure. 14 
Electrophysiological Study and Ablation Characteristics
Of the 20 patients, 90% (n=18/20) were inducible for sustained monomorphic VT. As shown in Table 2 , the mean number of VTs induced during programmed stimulation was 3.5 (range, 0-11) per patient. Average VT cycle length was 372±117 ms (range, 210-868 ms). Epicardial access was obtained in half (50%) of the patients. Average procedure time was 403.1±91.3 minutes, and the pLVAD was used for a mean of 287.2±88.8 minutes. For the entire cohort, there were 69 distinct sustained VT morphologies, and a cerebral oximetry (CerOx) saturation value of ≥55% was successfully maintained in 83% (n=57/69). Alternatively, 17% (n=12/69) required premature termination (with either pace-termination or external defibrillation) at some point during the case due to CerOx desaturation <55%. Of the patients who were initially inducible and in whom inducibility was measured after ablation (n=16), VT was terminated during ablation in 67% (n=12), and VT was rendered noninducible after ablation in 75% (n=12). Complete procedural success was achieved in 50% (n=8) of patients and partial procedural success in an additional 37% (n=6). Procedural failure, therefore, occurred in 2 patients (13%). Of note, for the 18 patients who were inducible for sustained VT, the decision of whether the clinical (or presumed clinical) VT was terminated during ablation was based on 12-lead ECG documentation in 6 patients and electrogram data (cycle length) in 12 patients.
Clinical Outcomes
With regard to safety outcomes, 15% (n=3) developed postoperative acute Acute Kidney Injury Network stage 1 kidney injury (ie, an absolute increase in serum creatinine of ≥0.3 mg/dL or percentage increase of 150%-200% from baseline), and all resolved within 72 hours (Table 3 ). There were also no cases of hepatic injury, which remained unresolved at the time of discharge. One patient (5%) demonstrated a decline in neurocognitive function, as defined by a decrease in MMSE ≥2 points from the baseline score, after the procedure. That patient, whose MMSE declined by 2 points, did not exhibit any clinically obvious cognitive changes, had no focal neurological deficits and did not require any neurological imaging. He was discharged home on postoperative day 5 without incident. Patients were generally successfully extubated within one day of the ablation (0.5±1.1 days) and were discharged at an average of 5.2±4.7 days postprocedure. All-cause mortality at 1 month was 10% (n=2). Of the 2 patients who died, neither of the deaths was preceded by ventricular arrhythmias. Before the index procedure, the first patient had presented with a recently diagnosed nonischemic cardiomyopathy (<3 months), incessant VT refractory to intravenous and oral antiarrhythmic drugs and a clinical suspicion of myocarditis. After the procedure, he was rehospitalized within 30 days with acute lung injury (biopsy-proven proliferative/organizing diffuse alveolar damage), and his death occurred 35 days after the VT ablation procedure secondary to massive hemoptysis soon after the diagnostic lung biopsy was performed. A second patient with preprocedural New York Heart Association Class III-IV heart failure was readmitted 33 days after the ablation procedure for acute decompensated heart failure, acute on chronic renal insufficiency, and hyperkalemia; his cause of death was secondary to pulseless electric activity. Inpatient monitoring and device interrogation demonstrated no evidence of ventricular arrhythmias before the presentation. In total, rehospitalization in the first 30 days was required in 25% (n=5), which included one patient with end-stage renal disease on dialysis who had undergone epicardial mapping/ ablation and was discharged home on aspirin, clopidogrel, and warfarin. He was readmitted 7 days later for pericardial effusion (with hemodynamic evidence of cardiac tamponade) and underwent an uncomplicated percutaneous drainage of the effusion. Two other patients were admitted for a presumed diagnosis of pneumonia and discharged home on oral antibiotics, and one patient was admitted for an atypical chest pain syndrome and discharged home without intervention or change in medical therapy.
Clinical Recurrence
The incidence of sustained VT and appropriate implantable cardioverter defibrillator therapy within the first month was 20% (n=4); all recurrences occurred in patients who had undergone the index procedure for electrical storm and whose substrate was nonischemic cardiomyopathy. Of these 4 patients with recurrences within the first month, 3 were originally classified as partial success (termination of the clinical VT but persistent inducibility of other sustained VT or no termination of the clinical VT but no longer inducible for VT after ablation) and 1 was classified as complete success. None of the patients with recurrences within the first month required a second ablation procedure.
Laboratory Assessment Before and After Ablation
Serum laboratory markers and left atrial pressure recordings were collected pre-and post ablation, as detailed in Table 4 . 
Effects of pLVAD on Cerebral Oxygenation and Blood Pressure During siVT
As shown in Table 5 , at siVT cycle length of 500 ms, no patients experienced cerebral desaturation (SctO2≤55%), regardless of whether the pLVAD was programmed to fullsupport (P8) or no-support (P0). Similarly, there was no significant difference in percent reduction in SctO2 from baseline with or without pLVAD support (P=0.43). At a faster siVT cycle length of 400 ms, however, 3 patients (15%) experienced cerebral desaturation to SctO2≤55% during no-support, whereas no patients experienced cerebral desaturation with the pLVAD at full-support (P=0.25). There was a concomitant significant attenuation in the reduction in SctO2 values from baseline with the pLVAD at full-support, compared with no-support, during siVT (average reduction = 4.9±3.5% at 
Incremental Benefit of CerOx Monitoring
Continuous arterial pressure and noninvasive CerOx were analyzed for all VT episodes >3 min. uVT was classified as an MAP<50 mm Hg, but, as per protocol, uVT was only prematurely terminated for cerebral desaturations <55%. Among the study cohort, there were a total of 50 episodes of VT lasting at least 3 min, occurring in 15 patients. As shown in Figure 1 , VT was maintained for significantly longer periods of time when CerOx was used as a marker of hemodynamic stability rather than when using standard MAP criteria. By using a threshold of SctO2≤55% (to arbitrate hemodynamic stability), rather than MAP<50 Figure 2 is an example of a patient with uVT, who benefited from the additional duration of entrainment mapping provided by both the pLVAD and the classifying hemodynamic stability by cerebral desaturation (rather than just arterial blood pressure criteria).
Discussion
The present study is the first to (1) evaluate the use of a percutaneous hemodynamic support device during ablation of scar VT prospectively and systematically, (2) assess the safety of a distinct cerebral desaturation threshold to guide the duration of mapping during uVT when using a miniaturized axial flow pump, and (3) demonstrate the incremental benefit of using CerOx compared with standard blood pressure criteria in arbitrating when VT is unstable necessitating termination-a benefit that translates to greater time for VT mapping, particularly for those VTs with the shortest cycle length.
CerOx Monitoring During VT Ablation
CerOx monitoring is being increasingly used to detect compromised brain and tissue perfusion in several clinical settings. 15 Indeed, neurocognitive function has been studied after brief episodes of controlled ventricular arrhythmias, such as during implantable cardioverter defibrillator testing. 16 However, to our knowledge, it has not been validated in patients undergoing VT entrainment/activation mapping (who are exposed to prolonged periods of VT). This study represents the first prospective application of this monitoring modality in patients undergoing VT mapping and ablation. Neuromonitoring during VT ablation is clinically relevant because (1) the optimal MAP necessary to maintain end-organ perfusion during hemodynamically significant VT is unknown, (2) cerebral desaturations (SctO2 values <50%-55%) seem to predict short-and long-term mortality and morbidity in patients undergoing cardiac surgery, and (3) CerOx monitoring can detect alterations in oxygenation earlier than other commonly used noninvasive methods. [17] [18] [19] Finally, in patients undergoing pLVAD-assisted VT ablation, during which there are frequently prolonged periods of nonpulsatile flow, the mean intravascular and cerebral perfusion pressures necessary to maintain organ and brain function may differ from conditions with pulsatile flow.
On the basis of prior reports, we chose a SctO2 desaturation value of <55% and demonstrated that, almost irrespective of arterial blood pressure, patients could be reasonably maintained in VT above this threshold. 20 In fact, by using cerebral saturation as a marker of stability, rather than standard MAP criteria (<50 mm Hg), the average duration of each VT episode (17.4 versus 10.7 minutes; P=0.028) and the total duration of VT for each patient (58.0 versus 35.7 minutes; P=0.047) were significantly longer, which translated into a nearly 40% increase in the duration of activation/entrainment mapping. The safety of this approach was validated by demonstrating that only a single patient experienced a decline in cognitive function (defined as a reduction in MMSE≥2 points from baseline), and the decline was mild (2 points). Three patients (15%) developed an acute decline in kidney function, all of which were Acute Kidney Injury Network stage 1 (at risk), and all of which resolved before discharge. 21 No patients developed advanced kidney injury (Acute Kidney Injury Network ≥ stage 2), and there were no instances of significant hepatic injury. In total, these findings suggest that CerOx monitoring is an important complimentary monitoring modality during scar VT ablation.
pLVAD Support During siVT
Percutaneous left ventricular assist support was associated with a more favorable hemodynamic profile compared with pharmacological agents alone in maintaining cerebral oxygenation during fast siVT. During fast siVT (300 ms) without mechanical cardiac support, more than half (53%) of the patients tested experienced significant cerebral desaturations (SctO2≤55%), compared with only 6% of patients with full pLVAD support (1.9-2.5 L/min). Furthermore, when the pLVAD was maintained at fullsupport, the average cerebral desaturation was significantly less at both moderate (400 ms) and fast (300 ms) pacing cycle lengths (4.9±3.5 and 6.3±4.3%, respectively) compared with the average cerebral desaturations without pLVAD support (6.9±7.1 and 14.1±6.1%). Whether the ability of the pLVAD to attenuate cerebral desaturation during fast siVT is equivalent to what its effects would be during true VT was not systematically tested in this study because the pacing site (and ventricular origin of the VT) can affect hemodynamic stability. Furthermore, this controlled experiment only involved the use of a single vasoactive agent (phenylephrine), and whether the same results would have been seen if alternative drugs had been used in isolation or combination is unknown. However, it is reassuring that the pLVAD significantly reduced the incidence of profound cerebral desaturations, when tested in a controlled fashion.
pLVAD-Assisted Scar VT Ablation
In a representative patient population, pLVAD-assisted scar VT ablation is safe and feasible. There was one procedurerelated major adverse event (pericardial effusion with tamponade 7 days postprocedure) and no instances of vascular injury or thromboembolism. A predefined anticoagulation and vascular access/closure protocol likely contributed to the absence of these latter 2 complications. 8 As previously reported, there can be electromagnetic interference between the magnetic-based mapping system (Carto 3) and the magnetic motor of the Impella pLVAD. 5, 8 In the current study, 9 of 20 patients experienced some degree of electromagnetic interference (requiring titration of pump performance), although none required complete cessation of pump function. The most common abnormality requiring titration of pump function was a temporary inability to acquire mapping points or distortion of the catheter position. If it is not possible to down-titrate the pump because of an uVT, it is possible to additionally display the ablation catheter based on the advanced catheter location function (ie, catheter location based on electric impedance field mapping). Furthermore, although not appreciated during this series, we cannot rule out the possibility that interference obscured the presence of low amplitude electrograms (on the EP recording system) during VT. The theoretical benefits of pLVAD-assisted VT ablation, which include (1) extending the duration of activation/entrainment mapping by maintaining end-organ perfusion and (2) left ventricular unloading during periods of sinus rhythm, were reflected in the high frequency of patients with at least 1 VT terminated during ablation (67%), the mean duration of VT per inducible patient (nearly 1 hour) and absence of differences in periprocedural left atrial filling pressures.
Limitations
The effects of pLVAD on scar VT ablation outcomes, compared with conventional approaches (substrate-based ablation alone or repetitive inductions and brief entrainment mapping to identify the critical isthmus) cannot be ascertained in the absence of a randomized trial. CerOx has been advocated as a marker of global tissue perfusion, but it does not take into account focal obstructions, such as renal artery stenosis. As such, all our patients underwent monitoring of intraprocedural urine output and periprocedural markers of organ dysfunction (lactate levels, creatinine, and hepatic enzymes). The lack of a control group precludes drawing definitive conclusions between the lack of either statistically or clinically significant changes in perioperative markers of end-organ perfusion/function (eg, lactate and creatinine) and the use of a pLVAD. We only used a single cutoff value to define significant cerebral desaturation. It is possible that either a higher value (eg, 60%) would be even safer or that a lower value (eg, 50%) would afford the same safety profile and yet be permissive of an even greater duration of entrainment/activation mapping. The 2.5-L/min pLVAD device used in this series maintained adequate cerebral perfusion/oxygenation (≥55%) in 83% of all distinct sustained VT morphologies, but 17% still required premature termination due to cerebral desaturation. Although this is a favorable hemodynamic support profile, it may indicate that certain patients require additional circulatory support. A newer generation of the Impella pLVAD provides a higher level of support (3.5-4 L/min), but only recently became available for commercial use and to our knowledge has not been tested in a systematic fashion in patients undergoing VT ablation. Although we demonstrated an incremental benefit of cerebral perfusion monitoring (compared with standard blood pressure criteria), the impact of increased time for mapping during ongoing VT remains unknown, as this study did not perform a direct comparison between the 2 monitoring strategies (cerebral perfusion versus blood pressure). Finally, all procedures in this series were performed under general anesthesia, which can blunt autonomic reflexes and the hemodynamic response during VT.
Conclusions
In patients with severe left ventricular dysfunction, pLVADsupported scar VT ablation is safe and feasible. Mechanical cardiac assistance with a miniaturized axial flow pump imparted a favorable hemodynamic profile compared with pharmacological agents alone in maintaining end-organ perfusion during simulated fast VT. CerOx is a complimentary monitoring modality during scar VT ablation, and avoidance of cerebral desaturations below a threshold of 55% may safely guide the duration of mapping during uVT.
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